Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease.
Cholinesterase inhibitors tested in clinical trials in Europe, the United States, and Japan include fewer than 10 drugs; however, most of these compounds have advanced to clinical phase III trials. Based on results related to a population of more than 8,000 patients, we conclude that several of these compounds have shown significant clinical efficacy and safety in the treatment of Alzheimer disease. There are, however, differences with regard to side effects. The major clinical effect is stabilization of cognitive function during a 6- to 12-month period with an improvement of behavioral symptoms. The long-term effect of cholinesterase inhibitors extending to a 2-year period was reported. Future applications of these drugs include treatment of other types of dementias such as Lewy bodies dementia, vascular dementia, and Down syndrome dementia. The combination of cholinesterase inhibitors with estrogens, antioxidants, and anti-inflammatories may represent a further improvement of the therapy. From an economical point of view, treatment with cholinesterase inhibitors is not cost neutral.
Giacobini
E
E
Department of Geriatrics, University Hospitals of Geneva, University of Geneva Medical School, Switzerland.
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D018450:Disease Progression; D006801:Humans; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors